The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

A stone tomb near Paris held generations of dead, but the people buried there did not all belong to the same world. That is ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...

SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria: Paris Wednesday, April 15, 2026, 09:00 Hrs [IST] The Europ ...

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Asahi Kasei acquires Aicuris, adding three antiviral assets targeting immunocompromised patients, with combined revenue ...